CLDX Q1 2024 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$156,000-83.9% YoY

Gross Profit

-$619,000-396.8% margin

Operating Income

-$41M-26030.8% margin

Net Income

-$33M-21030.8% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

-96.2%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$869M

Total Liabilities

$30M

Stockholders' Equity

$839M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$156,000	$967,000	-83.9%
Gross Profit	-$619,000	-$26M	+97.6%
Operating Income	-$41M	-$32M	-25.1%
Net Income	-$33M	-$29M	-11.7%

Revenue Segments

Grant

$154,00099%

Service

$2,0001%